TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06057207

Intervention type: DIAGNOSTIC_TEST
Intervention: serum levels of adiponectin
Description: adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: serum levels of adiponectin
Description: adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6
Description: IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: IL-6
Description: IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery

Intervention type: OTHER
Intervention: Postoperative systemic infflamation
Description: systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate\>90/min, body temperature \>38 C or \<36 C, WBC \>12 000 or \<4000, hyperventilation, CRP \>50mg/L, PCT \> 0.5 ug/L.

Intervention type: OTHER
Intervention: Postoperative systemic infflamation
Description: systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate\>90/min, body temperature \>38 C or \<36 C, WBC \>12 000 or \<4000, hyperventilation, CRP \>50mg/L, PCT \> 0.5 ug/L.

Intervention type: OTHER
Intervention: Postoperative complications
Description: Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic dehiscence, wound/local infection, postoperative bleeding, reoperation and systemic complications: sepsis, pneumonia, uroinfection, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation \>24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure. Length of ICU and overall hospital stay with final outcome after discharge from hospital will be documented.

Intervention type: OTHER
Intervention: Postoperative complications
Description: Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic dehiscence, wound/local infection, postoperative bleeding, reoperation and systemic complications: sepsis, pneumonia, uroinfection, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation \>24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure. Length of ICU and overall hospital stay with final outcome after discharge from hospital will be documented.
Study: NCT04591990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of AVP
Description: Administration of AVP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of AVP
Description: Administration of AVP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of placebo AVP
Description: Administration of placebo AVP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of placebo AVP
Description: Administration of placebo AVP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of placebo hydrocortisone
Description: Administration of placebo hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of placebo hydrocortisone
Description: Administration of placebo hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of hydrocortisone
Description: Administration of hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of hydrocortisone
Description: Administration of hydrocortisone
Study: NCT06149364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISKE
Description: The intervention will consist of an e-health software Programme that we have named Istumisen Keskeyttäminen (ISKE) will be installed on the desktop of participants.~Functionality of the software: the primary purpose of the software is to remind users (basically office-based workers) to take a break on a regular basis (recommended time 30 minutes).~At the end of the workday, the software provides information on the number of breaks taken and how long each lasted. The user will also have access to such information.~What happens during the prompted break: once the software prompts the user to take a break, she/he can click the Continue button to proceed with the break. The software will include activities that are suggested for the user to do during break. After the break, the record of the time (duration of the break, and when the break was taken) can be taken.
Study: NCT06482788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab (anti-PD-L1) + XELOX
Description: Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks).
Study: NCT06183827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency Medical Service intervention
Description: Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Medical Service intervention
Description: Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control.
Study: NCT06546956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Breathwork Intervention
Description: GRMT has three core components: respiratory regulation (i.e., sustained conscious connected breathing pattern into the upper chest where there is no pause between inhale and exhale), mindfulness of somatic sensations while breathing (i.e., interoceptive awareness with acceptance), and relaxation of physical tension. These components are the primary focus in every breathwork session. The intervention is delivered 1-on-1 in-person with a trained facilitator. Participants lay supine throughout the 60 minute session. The facilitator observes the participant's breathing pattern and guides the participant to apply the three core components. Each session ends with spontaneous, relaxed breathing and an opportunity to briefly share what happened during the session.
Study: NCT04491084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT3 Ligand (CDX-301)
Description: Fms-like tyrosine kinase 3 (FLT3) ligand is a potent hematopoietic growth factor that mobilizes stem cells and greatly increases the number of circulating dendritic cells (DCs) in blood and organs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody (CDX-1140)
Description: CD40 is a key molecule in the regulation of immune responses whose activity can be modulated using antibodies. CD40 is a tumor necrosis factor receptor superfamily member expressed on antigen presenting cells, including dendritic cells, as well as a host of other cell types, including a wide range of tumor cells
Study: NCT01491139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Given twice daily. Exposure will escalate by daily dose and duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Dose will be 35mg/m2 i.v. once weekly.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Total dose will be 70Gy in 35 fractions over 7 weeks.
Study: NCT04498325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Supplied by study
Study: NCT05797935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
Study: NCT06051838

Intervention type: PROCEDURE
Intervention: surgery
Description: if the patients is TD positive, we recommond careful surgery and pathological examination.

Intervention type: PROCEDURE
Intervention: surgery
Description: if the patients is TD positive, we recommond careful surgery and pathological examination.
Study: NCT04498325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied by study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for research purposes
Description: Prior to injection (Day 0), Day 7, and Day 14
Study: NCT05108350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
Description: SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
Study: NCT04498325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for research purposes
Description: Prior to injection (Day 0), Day 7, and Day 14

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood for research purposes
Description: Prior to injection (Day 0), Day 7, and Day 14

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for pharmacokinetic samples
Description: -Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal, oropharyngeal, or saliva swab
Description: -Prior to study treatment, Day 4(optional), Day 7, and Day 14

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal, oropharyngeal, or saliva swab
Description: -Prior to study treatment, Day 4(optional), Day 7, and Day 14

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasopharyngeal, oropharyngeal, or saliva swab
Description: -Prior to study treatment, Day 4(optional), Day 7, and Day 14

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for anti-drug antibody (ADA)
Description: Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for anti-drug antibody (ADA)
Description: Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood for anti-drug antibody (ADA)
Description: Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
Study: NCT05845762

Intervention type: DRUG
Intervention: Obinutuzumab Injection
Description: 1000mg intravenous injection

Intervention type: DRUG
Intervention: Obinutuzumab Injection
Description: 1000mg intravenous injection
Study: NCT04807205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Non-Invasive Treatment
Description: Self-controlled single-arm group using the Elite IQ device
Study: NCT06350435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (PFO) with metatarsal pads
Description: A pair of prefabricated foot orthoses, each with a metatarsal pad to be affixed underneath

Intervention type: DEVICE
Group type: OTHER
Intervention: Prefabricated foot orthoses (PFO) without metatarsal pads
Description: A pair of prefabricated foot orthoses only
Study: NCT05590416

Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
Study: NCT04484142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1062a
Description: DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
Study: NCT04491084

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
Study: NCT05113771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liafensine
Description: Liafensine
Study: NCT04491084

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
Study: NCT03113084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Heparin UQ subcutaneous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Heparin UQ subcutaneous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Heparin FK subcutaneous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study: NCT05122078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI
Description: Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
Study: NCT05113771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liafensine
Description: Liafensine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05339711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Pet Therapy/Robot Cat Group
Description: İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pet Therapy/Betta Fish Group
Description: İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
Study: NCT06180278

Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests
Description: Participants will have blood tests done at each scheduled visit (approximately every 6 months).

Intervention type: DRUG
Group type: OTHER
Intervention: Inebilizumab
Description: Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
Study: NCT06056960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Description: The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR.~Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem.
Study: NCT05326347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
Study: NCT05491200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel based short DAPT
Description: Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel based standard DAPT
Description: Prasugrel based DAPT for 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT guided revascularization
Description: OCT guided revascularization of the non-culprit lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guided revascularization
Description: Angio guided revascularization of the non-culprit lesions
Study: NCT03113084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Heparin FK subcutaneous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study: NCT04835714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441
Study: NCT05076032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXO-001
Description: OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXO-001
Description: OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
Study: NCT05932589

Intervention type: OTHER
Intervention: EEG and Auditory and Visual Evoked Potentials (AEP and VEP)
Description: Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.

Intervention type: OTHER
Intervention: EEG and Auditory and Visual Evoked Potentials (AEP and VEP)
Description: Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.

Intervention type: OTHER
Intervention: Clinical assessment
Description: Established clinical measures for RTT will be collected for RTT participants
Study: NCT05278546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB2109
Description: ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT04835714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441
Study: NCT04533646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (CGM)
Description: Participants will be required to wear a CGM to measure glucose trends